First Time Loading...

Fusion Antibodies PLC
LSE:FAB

Watchlist Manager
Fusion Antibodies PLC Logo
Fusion Antibodies PLC
LSE:FAB
Watchlist
Price: 5.5 GBX -18.52% Market Closed
Updated: Sep 30, 2023

Intrinsic Value

FAB doesn't have a meaningful market cap.
Intrinsic Value History
Fusion Antibodies PLC

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Fusion Antibodies PLC's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Example
Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Example
Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Example
Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis

Financials

Balance Sheet Decomposition
Fusion Antibodies PLC

Current Assets 3.2m
Cash & Short-Term Investments 1.2m
Receivables 1.5m
Other Current Assets 552k
Non-Current Assets 743k
PP&E 743k
Current Liabilities 1.1m
Accounts Payable 1.1m
Other Current Liabilities 83k
Non-Current Liabilities 270k
Long-Term Debt 250k
Other Non-Current Liabilities 20k
Efficiency
Fundamental Scores

FAB Profitability Score
Profitability Due Diligence

Fusion Antibodies PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROE
19/100
Profitability
Score

Fusion Antibodies PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

FAB Solvency Score
Solvency Due Diligence

Fusion Antibodies PLC's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Negative Net Debt
Low D/E
Short-Term Solvency
70/100
Solvency
Score

Fusion Antibodies PLC's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FAB Price Targets Summary
Fusion Antibodies PLC

There are no price targets for FAB.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

FAB Return Decomposition
Main factors of price return

What is price return decomposition?

FAB Price
Fusion Antibodies PLC

1M 1M
-3%
6M 6M
-86%
1Y 1Y
-89%
3Y 3Y
-97%
5Y 5Y
-92%
10Y 10Y
-96%
Annual Price Range
5.5
52w Low
4.9
52w High
59
Price Metrics
Average Annual Return 17%
Standard Deviation of Annual Returns 39.94%
Max Drawdown -98%
Shares Statistics
Market Capitalization 3.3m GBX
Shares Outstanding 59 453 700
Percentage of Shares Shorted
N/A

Company Profile

Fusion Antibodies PLC Logo
Fusion Antibodies PLC

Country

United Kingdom

Industry

Life Sciences Tools & Services

Market Cap

3.3m GBP

Dividend Yield

0%

Description

Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.

Contact

NORTHERN IRELAND
Belfast
Springbank Industrial Estate, 1 Springbank Road
+442890432800.0
https://fusionantibodies.com/

IPO

2017-12-18

Employees

54

Officers

CFO, Company Sec. & Director
Mr. James Fair
Chief Scientific Officer & Director
Dr. Richard John Buick Ph.D.
CEO & Director
Dr. Adrian Kinkaid Ph.D.
Founder
Prof. Jim Johnston
Director of Operations
Mr. Hugh Morgan Ph.D.
Consultant
Dr. Paul Gerard Kerr

See Also

Other Stocks
What is the Intrinsic Value of one FAB stock?

The intrinsic value of one FAB stock under the Base Case scenario is 23.72 GBX.

Is FAB stock undervalued or overvalued?

Compared to the current market price of 5.5 GBX, Fusion Antibodies PLC is Undervalued by 77%.